Apollon Formularies Plc (AQSE:APOL) told investors it has reopened its medical cannabis dispensary and treatment centre in Jamaica following certification for COVID-19 health and safety.
The company, in a statement, noted that Jamaica’s Tourism Product Development Company Ltd (TPDCo), an agent for the government, recently performed a COVID-19 compliance assessment of the facility in Negril.
"We are very proud of our Jamaican team for successfully passing all requirements leading to this certification,” said Stephen Barnhill, group chief executive.
“Since receiving this government required certification, Apollon Jamaica is again seeing patients at our pre-COVID levels.
“The health and safety of our patients are our primary concern, especially for those who are very ill and suffering. Having TPDCo Certification allows us to receive medical tourist patients and better enable all patients to have access to needed medical cannabis treatments."
Apollon Jamaica chief executive Paul Burke, meanwhile, added: “We want our patients to know that, whether they are local to Jamaica, or have travelled internationally to Jamaica, Apollon Jamaica will provide them with a safe and COVID-19 compliant environment for their treatment."